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The interferon (IFN) system, including various IFNs and IFN-inducible gene products, is well known for its
potent innate immunity against wide-range viruses. Recently, a family of cytidine deaminases, functioning as
another innate immunity against retroviral infection, has been identified. However, its regulation remains
largely unknown. In this report, we demonstrate that through a regular IFN-/ signal transduction pathway,
IFN- can significantly enhance the expression of apolipoprotein B mRNA-editing enzyme-catalytic polypep-
tide-like 3G (APOBEC3G) in human primary resting but not activated CD4 T cells and the amounts of
APOBEC3G associated with a low molecular mass. Interestingly, short-time treatments of newly infected
resting CD4 T cells with IFN- will significantly inactivate human immunodeficiency virus type 1 (HIV-1) at
its early stage. This inhibition can be counteracted by APOBEC3G-specific short interfering RNA, indicating
that IFN--induced APOBEC3G plays a key role in mediating this anti-HIV-1 process. Our data suggest that
APOBEC3G is also a member of the IFN system, at least in resting CD4 T cells. Given that the IFN-/
APOBEC3G pathway has potent anti-HIV-1 capability in resting CD4 T cells, augmentation of this innate
immunity barrier could prevent residual HIV-1 replication in its native reservoir in the post-highly active
antiretroviral therapy era.
Cellular APOBEC3G belongs to a family of proteins that
have cytidine deaminase activity (13, 25, 40). Albeit they could
restrict the mobility of endogenous retroviruses and long ter-
minal repeat (LTR) retrotransposons, their normal functions
in host cells remain largely unknown (3, 11). Recently, they
were identified to potently inhibit the replication of various
retroviruses, including human immunodeficiency virus (HIV),
simian immunodeficiency virus, and type C retroviruses, as well
as hepatitis B virus and endogenous retroviruses (2, 8, 11, 19,
25, 35, 42). APOBEC3G can either edit the newly synthesized
viral DNA or have an inhibitory effect at another site(s) of the
viral life cycle (16, 17, 33, 40). For surviving, retroviruses en-
code various gene products to counteract the inhibition of
cytidine deaminases. In the case of HIV-1 and many other
lentiviruses, virion infectivity factor (Vif) is encoded to effec-
tively counteract the antiviral effect of APOBEC3G and
APOBEC3F by facilitating the degradation of these cytidine
deaminases (25, 36, 42). Alternatively, a recent study has
shown that in resting primary CD4 T cells, APOBEC3G may
play a major role to significantly restrict wild-type HIV-1 rep-
lication at the early stage of the viral life cycle (5). These newly
discovered defense and antidefense mechanisms from the host
have prompted us to further exploit the regulatory network of
this innate immunity system.
Alpha interferon (IFN-) is one of a cytokine family that
exhibits antiviral properties and was discovered as an antiviral
agent during studies on virus interference. It exerts antiviral
activity through multiple pathways, including PKR (double-
stranded RNA-dependent protein kinase)/eukaryotic initiation
factor 2, oligoadenylate synthetase-mediated RNase L, aden-
osine deaminase, and protein GTPase Mx/nitric oxide syn-
thetase (24). In this report, we suggest that in addition to these
antiviral pathways, IFN- exerts its anti-HIV-1 activity through
APOBEC3G in resting CD4 T cells. We have shown that
APOBEC3G mRNA and protein level are substantially up-
regulated in the presence of exogenous human (h)-IFN- in
resting CD4 T cells derived from human peripheral blood
mononuclear cells (PBMC). Importantly, the low-molecular-
mass (LMM)-associated APOBEC3G is also enhanced. The
potent and irreversible inhibitory effect of IFN- upon reverse
transcription and viral infectivity, which is mediated by
APOBEC3G, has raised the possibility that enhancement of
APOBEC3G protein level may completely destruct residual
HIV-1 replication in resting CD4 T cells.
MATERIALS AND METHODS
Isolation and culture of primary cells. The fresh human PBMC were isolated
from healthy human subjects (provided by the blood bank of Thomas Jefferson
University Hospital) by using histopaque (Sigma). The resting primary CD4 T
lymphocytes were isolated from PBMC by using CD4 T cell isolation kit II
(Miltenyl), with which PBMC were depleted of CD8, CD14, CD19, CD56,
CD36, CD123, CD235a, CD16, and anti-T-cell receptor / cells by direct
immunomagnetic labeling, using antibodies against their respective surface
markers. The isolated resting CD4 T cells were maintained in RPMI 1640-
conditioned medium. The activated primary CD4 T cells were obtained by
stimulation with phytohemagglutinin (PHA) (5 g/ml) for 48 h, followed by
maintenance with interleukin-2 (IL-2) (25 U/ml; Sigma).
Construction of chimeric report gene. The promoter of h-ABOBEC3G (1.95
kb) was generated by PCR, using an elongase amplification system (Invitrogen)
with primers 5-GATACGCGTGCTAGCAAAGATGAAAACAATCCCACCT
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CACCCAGCG-3 (sense) and 5-GATAGATCTAAGCTTCTGGCAGAGGG
ACCTCTGATAAAGACAGGCCGCTCTGTGC-3 (antisense). The template
DNA was extracted from H9 cells using a genomic DNA isolation kit (Sigma).
Cleaved 1.95-kb DNA with restriction enzymes NheI and HindIII was ligated
into pGL3 basic plasmid (Promega) harboring a luciferase reporter gene. The
1.5-kb, 0.9-kb, and 0.4-kb promoters of h-APOBEC3G were produced by PCR or
cleaved by various restriction enzymes. The 1.5-kb promoter DNA containing the
IFN-stimulated response element (ISRE) mutant (GTTTCACTTCTT to GTT
TCACGGCTT) was generated by PCR-based mutagenesis.
siRNA synthesis. The short interfering RNAs (siRNAs) used in the experi-
ments were chemically synthesized by Dharmacon. The APOBEC3G-specific
siRNA was siGENOME SMART pool (catalog no. M-013072); the interferon
regulatory factor 9 (IRF9)-specific siRNA was siGENOME SMART pool (cat-
alog no. M_020858-01). The luciferase-specific siRNA served as a negative con-
trol. The sequence in its positive strand is 5-CTTACGCTGAGTACTTCGA-3.
Transfection. The chimeric plasmids and control plasmids were transfected
into 293T cells using Fugene 6 reagent (Roche). The plasmids or siRNAs were
transfected into primary CD4 T cells, using an Amaxa nucleofector apparatus
(Amaxa Biosystems). The U-14 program was selected for the resting CD4 T cells,
while the T-23 program was selected for the activated CD4 T cells. The proce-
dures suggested by the manufacturer were followed. The cells were then main-
tained in RPMI 1640-conditioned medium.
Flow cytometric analysis. CD4 T cells were isolated from fresh human PBMC,
using MACS CD4 T cell isolation kit II (Miltenyi), and maintained in RPMI me-
dium supplemented with 10% fetal bovine serum. For activation, the cells were
stimulated with PHA (5 g ml1) for 48 h, followed by IL-2 (25 U ml1) for 24 h,
and then subjected to flow cytometric analysis as described previously (34). For
analysis of the effect of siRNA transfection, fresh resting CD4 T cells were trans-
fected with various siRNAs, using an Amaxa nucleofector II apparatus, and sub-
jected to flow cytometric analysis at 72 h posttransfection.
Gel mobility shift assay. Nuclear proteins were prepared by using the urea
extraction method, and the gel mobility shift assay was performed as described
previously (14, 15). Briefly, resting CD4 T cells treated with or without recom-
binant IFN- (300 U/ml; Sigma) for 7 h were lysed with 0.6% NP-40 lysis buffer.
After the cells were vortexed for 15 seconds, nuclei were pelleted by centrifu-
gation at 6,000  g for 20 s and resuspended in 10-pellet volumes of extraction
buffer. After incubation on ice for 30 min, the mixture was centrifuged at 12,000 
g for 10 min. The supernatant was collected, and glycerol was added to a final
concentration of 10%. The protein concentration of the nuclear extract was
determined by the Lowry method. Conversely, synthesized wild-type ISRE-like
FIG. 1. Expression of APOBEC3G is up-regulated by IFN- in human resting CD4 T cells. (A) Time course study. Recombinant IFN- (300
U/ml; Sigma) was added to the cultures of resting (left) or activated (right) primary CD4 T cells. The expression of APOBEC3G protein was
detected at various time points. (B) Dose-dependent effect of IFN- upon APOBEC3G expression in resting (left) or activated (right) CD4 T cells.
Resting or activated CD4 T cells were treated with IFN- at different concentrations. The cell lysates were prepared at 7 h posttreatment and
subjected to Western blotting. (C) The resting CD4 T cells were prepared from four independent healthy blood donors and were treated with
IFN- for 7 h. The cell lysates were then prepared and subjected to Western blot analysis. Loading controls were carried out by detecting 	-actin
expression with an immunoblotting assay using mouse monoclonal antibody to human 	-actin. The data (A to C) represent at least three
independent experiments. (D) Flow cytometric analysis of activation status of resting CD4 T cells after nucleofection or activated CD4 T cells. The
cells were labeled with anti-CD25 fluorescein isothiocyanate antibody, anti-CD69 allophycocyanin antibody, or an isotype control (arrows) and
subjected to fluorescence-activated cell sorter analysis. Similar results were obtained using cells from four different donors.
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nucleotide (5-CTGGCTGTTTCACTTCTTTTGTGT-3) and mutant nucleotide
(5-CTGGCTGTTTCACGGCTTTTGTGT-3) and their complementary strands
(5-ACACAAAAGAAGTGAAACAGCCAG-3 and 5-ACACAAAAGCCGTGA
AACAGCCAG-3) were annealed to form double-stranded DNA and then la-
beled with [-32P]dATP. The labeled probes were purified with a G-25 column
(Amersham). The nuclear extract (10 g) was incubated with 2 g poly(dI-dC)n
in 50 l binding buffer on ice for 20 min. Approximately 2  104 to 6  104 cpm
(1 to 5 ng) of a 32P-labeled double-stranded DNA fragment was added to the
preincubated nuclear extract mixture and continued to be incubated on ice for 50
min. DNA-protein complexes were resolved on 6% polyacrylamide gels in 0.5
Tris-borate-EDTA buffer at 350 V for 3 h. The gel was dried and autoradio-
graphed overnight. For the competition experiment, 100-fold excess unlabeled
competitor oligonucleotides were added to the reaction mixture before the
labeled DNA fragment was added.
Chromatin immunoprecipitation assay. The experiment was performed as
described previously, with minor modifications (7, 20). Briefly, resting CD4 T
cells isolated from human PBMC were cultured in 12-well plates (2  107/well)
and treated with or without IFN- (300 U/ml) for 7 h. Formaldehyde was added
directly to the medium to a final concentration of 1% and incubated in 37°C for
10 min. The fixed cells were washed twice, lysed with 200 l sodium dodecyl
sulfate (SDS) lysis buffer (Upstate), and then subjected to sonication. The son-
icated samples were diluted to 2 ml. Immunoprecipitation was carried out by the
addition of mouse anti-STAT2 antibody (Santa Cruz) or anti-	-actin antibody
(Sigma) and incubation at 4°C overnight. Protein A agarose-salmon sperm DNA
beads (Upstate) were applied to the reaction mixture and incubated at 4°C for
1 h. After being washed, the bead-associated DNA was eluted with fresh elution
buffer (1% SDS, 0.1 M NaHCO3) and recovered with 5 M NaCl at 65°C for 4 h.
A DNA sample was extracted with phenol-chloroform, followed by ethanol
precipitation. Purified DNA samples were amplified with PCR for 30 cycles,
using two primer pairs. Oligo 1 primers are for target cis element sequences:
5-CAAAGGCGGTCATCTGTTGTCAGC-3 (upstream, nucleotides [nt]
1126 to 1103) and 5-GAAGTGAAACAGCCAGTTTCTCCC-3 (down-
stream, nt 935 to 958). Oligo 2 primers served as a negative control: 5-AT
CAGAAGACCACAGACCATGGAC-3 (upstream, nt 1715 to 1691) and
5-GACAGAGTGAGACTCCATCTCA-3 (downstream, nt 1486 to 1507).
Luciferase assay. Luciferase enzymatic activity was detected with luminous
reaction substrate (Promega) by using an FB 12 luminometer (DLR). The
instructions of the manufacturer were followed.
Western blotting. Proteins were extracted using CytoBuster protein extraction
reagent (Novagen) and then quantified by a bicinchoninic acid protein assay
reagent kit (Pierce). The procedure recommended by the manufacturer was
followed. The immunoblotting assays were performed as described previously
(39, 40). Rabbit polyclonal anti-APOBEC3G antibody was contributed by
ImmunoDiagnostics, Inc., and obtained from the NIH AIDS Research and
Reference Reagent Program.
Real-time RT-PCR. Resting CD4 T cells were treated with or without IFN-
for various hours or various doses, followed by RNA extraction using TRIzol
reagent (Invitrogen). RNA was then reverse transcribed using an iScript cDNA
FIG. 1—Continued.
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synthesis kit (Bio-Rad). The cDNAs of APOBEC3G and GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) were amplified using iQSYBR green super-
mix (Bio-Rad) in a PCR buffer containing 100 mM KCl, 40 mM Tris-HCl (pH
8.4), 0.4 mM of each deoxynucleoside triphosphate, 50 U/ml iTaq DNA poly-
merase, 6 mM MgCl2, SYBR green I, and 20 nM fluorescein. Quantitative
reverse transcription (RT)-PCR for each sample was normalized using GAPDH
as an endogenous control. The primers for h-APOBEC3G detection were 5-TC
AGAGGACGGCATGAGACTTAC-3 (upstream) and 5-AGCAGGACCCA
FIG. 2. IFN- enhances APOBEC3G mRNA expression in resting CD4 T cells. Total cellular RNA was extracted from resting CD4 T cells at
7 h after the addition of IFN- (300 U/ml) into cell culture. The mRNA level of APOBEC3G was analyzed by real-time RT-PCR. (Left) Time
course study. The amounts of APOBEC3G mRNA at 3 h, 6 h, and 9 h are significantly higher than that at time zero (asterisk, P 
 0.001, t test).
(Right) Dose-dependent experiment. The amounts of APOBEC3G mRNA induced by 300 U/ml, 600 U/ml, and 1,000 U/ml of IFN- are
significantly higher than that without IFN- treatment (, P 
 0.001, t test).
FIG. 3. Transcriptional regulation of APOBEC3G expression by IFN-. (A) (Top) The APOBEC3G promoter at a 1.95-kb length was amplified
using genomic DNA from H9 cells as a template and subjected to sequential deletion analysis. An ISRE-like sequence was identified in 1.95-kb DNA.
(Bottom) The APOBEC3G promoters at various lengths (0.4 kb, 0.9 kb, 1.5 kb, and 1.95 kb) were constructed and placed upstream of the luciferase
reporter gene. (B) Resting (left) or activated (right) CD4 T cells were transfected with various chimeric plasmids, followed by treatment with or without
IFN- (300 U/ml). Cell lysates were prepared at 24 h posttransfection, and luciferase activity was examined. The addition of IFN- into resting CD4 T
cells significantly enhances the activities of the 1.5-kb and 1.9-kb promoters (, P 
 0.001, t test) (right). (C) The resting (left) or activated (right) CD4
T cells were transfected, respectively, with a 1.5-kb promoter plasmid or plasmid containing a 1.5-kb promoter with a mutant ISRE-like sequence and
treated with or without various siRNAs or treated with or without IFN- (300 U/ml). The cell lysates were harvested at 24 h posttransfection, followed
by detection of luciferase activity. In resting CD4 T cells, compared with the activity of the 1.5-kb promoter, the 1.5-kb M promoter, the 1.5-kb M
promoter treated with IFN-, or the 1.5-kb promoter treated with IFN- and IRF9-specific siRNA, the activity of the 1.5-kb promoter treated with IFN-
or the 1.5-kb promoter plus green fluorescent protein (GFP)-specific siRNA treated with IFN- was significantly increased (, P
 0.001, t test). (D) The
resting CD4 T cells were transfected with or without IRF9-specific siRNA. At certain time points, the cell lysates were subjected to immunoblotting
using anti-IRF9 antibody (left). The resting CD4 T cells transfected with or without various siRNAs were treated with or without IFN- (300 U/ml). Cells
were collected at 7 h post-IFN- treatment, and the APOBEC3G level (right) was analyzed using immunoblotting. NC, negative control plasmid without
any promoter; PC, positive control plasmid containing cytomegalovirus promoter; 1.5kb-M, 1.5-kb chimeric plasmid containing mutations in the
ISRE-like sequence; siIRF9, IRF9-specific siRNA; siGFP, GFP-specific siRNA.
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GGTGTCATTG-3 (downstream). The primers for GAPDH detection were
5-GAAGGTGAAGGTCGGAGT-3 (upstream) and 5-GAAGATGGTGATG
GGATTTCC-3 (downstream). Data analysis and calculation were performed
according to the 2CT comparative method applied for the MyiQ single-color
real-time PCR detection system (Bio-Rad).
Fast-protein liquid chromatography (FPLC) assay. The resting and activated
CD4 T cells were treated with or without IFN- (300 U/ml). The cells were
collected after 7 h of treatment and lysed with lysing buffer (6 mM Na2HPO4, 4
mM NaH2PO4, 1% NP-40, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 0.1%
proteinase inhibitor cocktail). The concentrated 3-ml protein samples were
loaded into a HiPrep 26/60 Sephacryl S-300 HR column (Amersham Bio-
sciences), driven by the LKB FRAC-100 system (Pharmacia) at a flow rate of 1.0
ml/min, and eluted with elution buffer (0.05 M sodium phosphate, 0.15 M NaCl,
0.04% NaN3, pH 7.2). All fractions were concentrated with a centrifugal filter
(Amicon Ultra-15 10000 MWCO; Millipore) and subjected to SDS-polyacryl-
amide gel electrophoresis (PAGE) analysis, followed by Western blot analysis.
FIG. 3—Continued.
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Intracellular reverse transcription. Resting CD4 T cells purified from human
PBMC were transfected with various siRNAs. At 72 h postinfection, DNase-
treated HIV-1NL4-3 viruses (5 ng p24 equivalent) were allowed to infect the
resting or PHA-stimulated CD4 T cells with or without IFN-. After 4 h, the
unbound viruses were removed and infected cells were maintained in the con-
ditioned medium in the presence of soluble CD4 molecule (10 g/ml) and with
or without IFN- (300 U/ml). The cells were harvested at 48 h postinfection.
DNA was extracted and subjected to PCR and Southern blot analysis, as de-
scribed previously (9, 38).
Viral infection. Wild-type HIV-1NL4-3 viruses were produced from 293T cells
by transfection with pNL4-3. After determination of the 50% tissue culture
infective dose, viruses were then allowed to infect the resting CD4 T cells (3 
106) transfected with or without APOBEC3G-specific siRNA or luciferase-spe-
cific siRNA. The infected CD4 T cells were cultured in 12-well plates, treated
with or without IFN- (300 U/ml) for various periods, and subjected to stimu-
lation with PHA (5 g/ml) or without PHA for 48 h. The activated cells were
maintained in the RPMI 1640-conditioned medium containing IL-2 (25 U/ml).
The supernatant in each well was harvested every 3 or 4 days, and p24 detection
was performed using an enzyme-linked immunosorbent assay (ELISA) kit as
described previously (38).
RESULTS
Expression of APOBEC3G is up-regulated by IFN- in hu-
man resting CD4 T cells. In order to search for the cellular
factor(s) that regulates the expression of APOBEC3G, we
have examined the possible influence of various cytokines on
the expression of APOBEC3G, based upon the putative bind-
ing sites of various transcriptional factors in the promoter
region of APOBEC3G. We found that IFN- can significantly
enhance the expression of APOBEC3G in resting primary
CD4 T cells isolated from PBMC of healthy blood donors (Fig.
1A to C). The resting condition of these cells was further
confirmed by examining the expression of CD25 and CD69
markers analyzed by fluorescence-activated cell sorting (Fig.
1D). This enhancement cannot be observed in T-cell lines such
as H9, C8166, and SupT-1 (data not shown). The enhancement
of APOBEC3G expression by IFN- in resting CD4 T cells
FIG. 4. IFN--induced ISGF3 complex binds to ISRE-like sequence. (A) The ISRE-like sequence in the h-APOBEC3G promoter specifically
binds to nuclear proteins from resting CD4 T cells treated with IFN-. Resting CD4 cells were treated with or without IFN- (300 U/ml) for 7 h,
and nuclear proteins were extracted. 32P-labeled nucleotides containing the ISRE-like sequence or its mutant were incubated with or without
nuclear proteins. As a control, anti-STAT2 antibody was added for supershifting. The mixtures were resolved in a 6% native PAGE gel. The gel
was dried and autoradiographed overnight. (B) Chromatin immunoprecipitation assay. The resting CD4 T cells were treated with or without IFN-
and fixed with formaldehyde. After sonication to break down long chromatin filament, the samples were subjected to immunoprecipitation with
anti-STAT2 or anti-	-actin antibody. DNA was then extracted from the precipitated complex and subjected to PCR with two primer pairs. The
PCR products were analyzed by electrophoresis.
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becomes highly notable at 5 h postincubation (Fig. 1A) and is
dose dependent (Fig. 1B). Importantly, this phenomenon
can be observed in resting primary CD4 T cells isolated from
multiple healthy blood donors (Fig. 1C). In contrast to its
action in resting CD4 cells, IFN- inhibits the expression of
APOBEC3G in activated primary CD4 cells (Fig. 1A and B).
Transcriptional regulation of APOBEC3G expression by
IFN-. The amount of mRNA of APOBEC3G in resting CD4
T cells is increased in the presence of IFN- (Fig. 2), suggest-
ing that the enhancement of APOBEC3G expression by
IFN- could take place at the transcriptional level. We have
identified an ISRE-like sequence in the promoter region of
APOBEC3G, which is located at the region spanning bp
1074 to 1063 (Fig. 3A). In the presence of this ISRE,
IFN- can significantly enhance the promoter activity of
APOBEC3G in resting CD4 T cells (Fig. 3A and B). Mutations
introduced at the ISRE site significantly decreased the aug-
menting effect of IFN- upon the promoter activity of
APOBEC3G (Fig. 3C). As IRF9 is part of the IFN-stimulated
gene factor 3 (ISGF3) complex and is required for the inter-
action between the ISGF3 complex and ISRE (31), we then
examined whether inhibition of IRF9 expression can block the
IFN--induced activity of the APOBEC3G promoter. As the
expression of IRF9 is effectively decreased through an RNA
interference assay (Fig. 3D), the enhancement of APOBEC3G
promoter activity by IFN- is inhibited, either in an
APOBEC3G promoter-driven luciferase system (Fig. 3C) or in
a wild-type APOBEC3G expression system (Fig. 3D). In vitro
gel mobility shifting experiments indicate that this ISRE se-
quence can specifically bind to the nuclear proteins extracted
from resting primary CD4 T cells treated with IFN- but not
those without IFN- treatment. The binding between the nu-
clear proteins and the ISRE-like sequence can be inhibited by
a sequence-specific competitor. Mutations at the ISRE region
can prevent this interaction. Anti-STAT2 antibody can super-
shift the binding complex, further suggesting that the ISGF3
complex, which is composed of STAT1, STAT2, and IRF9, can
specifically bind to the ISRE region (Fig. 4A). Moreover, the
IFN--induced interaction between the ISGF3 complex and
the ISRE element in the APOBEC3G promoter region in
resting CD4 T cells can be identified by a chromatin immuno-
precipitation assay, in which anti-STAT2 antibody can specif-
ically capture the cis ISRE (Fig. 4B). All of these results indi-
cate that IFN- up-regulates the activity of the APOBEC3G
promoter through the classical IFN- pathway (24). Interest-
ingly, the promoter activity of APOBEC3G in activated CD4 T
cells cannot be significantly affected by IFN- (Fig. 3B). There-
fore, the decreased expression of APOBEC3G in activated
CD4 T cells in the presence of IFN- could be due to the
accelerated degradation of APOBEC3G.
IFN- enhances the association of APOBEC3G with an
LMM. It has been shown that in resting CD4 T cells,
APOBEC3G is associated with an LMM by which it is active
and able to perform DNA deamination and inhibit HIV-1
replication (5). To investigate the status of increased
APOBEC3G induced by IFN- in resting CD4 T cells, we
performed FPLC assays to analyze the complex with which the
increased APOBEC3G is associated. We found that the ma-
jority of increased APOBEC3G induced by IFN- in resting
CD4 T cells is associated with an LMM (Fig. 5). These data
suggest that, as described previously (5), the increased
APOBEC3G by IFN- could have anti-HIV-1 activity. It is
interesting that albeit IFN- decreases the concentration of
APOBEC3G in activated CD4 T cells, IFN- induces the as-
sociation of APOBEC3G with an LMM in activated CD4 T
cells (Fig. 5).
IFN- potently inhibits HIV-1 replication in initially resting
CD4 T cells through APOBEC3G. It has been well known that
FIG. 5. Effect of IFN- upon APOBEC3G in an LMM complex. The resting primary CD4 T cells were treated with or without IFN- (300
U/ml) and harvested at 7 h after stimulation. The supernatants of cell lysates were concentrated and loaded into an FPLC column with 0.05 M
sodium phosphate at a flow rate of 1.0 ml/min. Eluted fractions were subjected to SDS-PAGE, followed by an immunoblotting assay with
anti-APOBEC3G antibody. Cell lysates from the activated CD4 T cells with or without IFN- treatment were also analyzed as controls.
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in cell cultures, HIV-1 could initially infect resting primary
CD4 T cells and stay in a preintegration latency condition.
Upon T-cell activation, HIV-1 can extend its life cycle and
generate the progeny viruses (4, 29, 37). Recent studies have
suggested that APOBEC3G associated with an LMM could be
largely responsible for this preintegration latency (5). It is
demonstrated that APOBEC3G-specific siRNA is capable of
down-regulating the expression of APOBEC3G, thus allowing
HIV-1 to infect resting CD4 T cells in a single-round infection
assay (5). To further verify this interesting phenomenon, we
have examined the effect of APOBEC3G-specific siRNA upon
the replication of wild-type HIV-1 in resting CD4 T cells. We
found that APOBEC3G-specific siRNA indeed can rescue the
wild-type HIV-1 replication in resting CD4 T cells (Fig. 6). To
investigate the effect of the IFN-/APOBEC3G pathway upon
HIV-1 replication in resting CD4 T cells, IFN- was added to
cell cultures during the resting stage of cells to enhance the
expression of APOBEC3G. As shown in Fig. 7B, IFN- treat-
ment can significantly inhibit reverse transcription in resting
CD4 T cells. However, APOBEC3G-specific siRNA, which can
effectively decrease APOBEC3G in resting CD4 T cells (Fig.
7A), can rescue reverse transcription and counteract the inhib-
itory effect of IFN-. Further, a single-round infection exper-
iment has also demonstrated that IFN- potently inhibits
the viral infectivity at an early event (Fig. 8A, lanes 3 and 7).
As this inhibitory effect can be significantly rescued by
APOBEC3G-specific siRNA (Fig. 8A, lane 5), we propose that
the IFN-/APOBEC3G pathway has a potent antiviral activity
in resting CD4 cells. It is notable that we used a thin-layer
chromatographic assay to process the chloramphenicol acetyl-
transferase (CAT) assay. After an enzymatic reaction, the hy-
drophobic chloramphenicol was extracted with ethyl acetate.
During this procedure, a minor contamination from aqueous
phase may occur. These very few hydrophilic materials could
slightly change the shape of spots formed by modified or un-
modified chloramphenicol. Under the influence of the minor
hydrophilic materials, the center part of the spots becomes the
thinnest part of the spots (hollow). However, it should not
affect the final result. The density of whole spots formed by
modified or unmodified 14C-labeled chloramphenicol is mea-
sured by a phosphorimager. Similar results have been reported
by other researchers (27).
As PKR- and RNase L-specific siRNA, which can effectively
decrease the concentration of PKR or RNase L in resting CD4
T cells (Fig. 8B), cannot rescue the inhibitory effect of IFN-
(Fig. 8A, lanes 9 and 11), it is unlikely that PKR or RNase L,
which are also members of the IFN--induced signaling path-
way, mediate the antiviral activity of IFN- in resting CD4 T
cells. We have also exploited the anti-HIV-1 activity of IFN-
in resting CD4 T cells with wild-type viruses. As shown in Fig.
8C and D, IFN-, even if only incubated with infected resting
T cells for the first 24 to 96 h and then completely removed,
significantly inhibits the viral replication while the cells are in
activating status, indicating that IFN- inactivates a significant
FIG. 6. APOBEC3G-specific siRNA makes the resting CD4 T cells purified from fresh human PBMC permissive to wild-type HIV-1
replication. The resting CD4 T cells (3  106) were transfected with or without APOBEC3G-specific siRNA (100 nmol/ml) or luciferase-specific
siRNA (100 nmol/ml). After 72 h, the transfected cells were infected with HIV-1NL4-3 viruses (multiplicity of infection, 0.1). After being washed,
the infected cells were cultured in RPMI 1640-conditioned medium without any mitogen or cytokine stimulation. The p24 antigen of HIV-1 viruses
in the supernatant was detected via ELISA every 3 or 4 days.
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amount of viruses which are at their preintegration stage. As a
control, IFN- that has been incubated with activated T cells at
the same dose for the first 72 h does not exert such a significant
inhibitory effect upon HIV-1 replication (Fig. 8C). Similar
to what was seen with the single-round infection assay,
APOBEC3G-specific siRNA can also significantly reduce
the inhibitory effect of IFN- upon wild-type HIV-1 replica-
tion (Fig. 8D). This result also suggests that IFN- could
inhibit viral infectivity through enhancing the expression of
APOBEC3G. Of note, transfection with APOBEC3G-specific
siRNA or luciferase-specific siRNA did not increase the ex-
pression of CD25 and CD69 on the surface of resting CD4 T
cells (Fig. 1D), indicating that these treatments do not affect
the resting status of primary CD4 T cells. To investigate whether
the DNA deamination activity of APOBEC3G is involved in the
IFN--induced anti-HIV-1 activity in resting CD4 T cells, we
examined 59 viral sequences (32,450 total nucleotides in env or 3
LTR region) of PCR products generated from the infected cells
at 14 days postinfection. We also examined 46 viral sequences
(25,300 total nucleotides) generated from the newly synthesized
viral DNA at 48 h postinfection. These infected cells were initially
treated with IFN- but without any siRNA, followed by mitogen
stimulation (Fig. 8C). No significant G-to-A hypermutation has
been identified in these sequences (data not shown). Therefore, it
is unlikely that APOBEC3G-induced deamination in nascent vi-
ral DNA plays a major role in this antiviral activity of the IFN-
/APOBEC3G pathway.
DISCUSSION
The innate immunity is imperative during the early phase of
host defense against various infections before an antigen-spe-
cific adaptive immune response is induced. Given that the
majority of CD4 T cells in vivo are in a resting stage,
APOBEC3G could function as a highly effective barrier to
prevent extensive replication of HIV-1 and subsequently re-
strict its massive cytopathic effect on CD4 T cells. Unfortu-
nately, this barrier is not yet reliable enough. It has been
known that in cell cultures, HIV-1 could initially infect resting
primary CD4 T cells and stay in a preintegration latency
condition. Work from Greene’s lab has indicated that
APOBEC3G may play a major role in restricting HIV-1 rep-
lication in resting CD4 T cells (5). It seems that APOBEC3G,
at its native concentrations in resting CD4 T cells, only tran-
siently blocks the reverse transcription of HIV-1 and cannot
completely eradicate the viruses, resulting in a preintegration
latency. When resting CD4 cells are activated, a large amount
of these viruses continue to complete their life cycle and gen-
erate progeny viruses, indicating that APOBEC3G in resting
CD4 T cells could just transiently block reverse transcription
FIG. 7. APOBEC3G-mediated inhibitory effect of IFN- upon intracellular reverse transcription. (A) Resting CD4 T cells were transfected with
APOBEC3G-specific siRNA (100 nmol/ml) or luciferase-specific siRNA (100 nmol/ml). Cells were collected at different time points after transfection,
and APOBEC3G levels were detected by an immunoblotting assay. (B) Resting or activated CD4 T cells, transfected with or without various siRNAs,
were infected by DNase-treated HIV-1 viruses. The infected cells were treated with or without IFN-. At 48 h postinfection, the cells were harvested and
viral gag DNA was detected with PCR, using SK38/SK39 as the primer pair and SK19 as the probe. As a control, 	-globin DNA was also detected.
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and viral replication. Our data have demonstrated that IFN-
is able to enhance the anti-HIV-1 activity of APOBEC3G by
increasing its concentration and keeping its association with an
LMM. As very few or no viruses can be recovered after acti-
vation of the infected CD4 T cells (Fig. 8A and C to D),
IFN--enhanced APOBEC3G can significantly inhibit reverse
transcription and irreversibly inactivate HIV-1 viruses in the
preintegration stage. This effect is in contrast to the transient
FIG. 8. IFN- potently inhibits HIV-1 replication in initially resting CD4 T cells through APOBEC3G. (A) APOBEC3G-specific siRNA mediates
potent inhibition of IFN- upon HIV-1 infectivity in a single-round viral infection. Three plasmids, pMD.G, pCMVR8.2, and HIV-CAT (derived from
pHR by replacing the LacZ gene with the CAT gene), were transfected into 293T cells (18). The supernatants were harvested after 72 h, and the
recombinant viruses were further concentrated by ultracentrifugation. Conversely, the resting CD4 T cells purified from human PBMC were transfected
with various siRNAs. After 72 h, the cells were infected with the concentrated recombinant viruses (20 ng p24 equivalent per cell sample [2  106]) with
or without IFN- treatment. After 4 h, the unbound viruses were washed off and the infected cells were maintained in a conditioned medium with or
without IFN- (300 U/ml). At 96 h postinfection, IFN- was removed and PHA and IL-2 were added to activate the cells. After 48 h, the cells were
harvested and a CAT assay was performed. (B) Effect of IFN- and siRNA upon the expression of PKR and RNase L in resting CD4 T cells. The resting
CD4 T cells purified from human PBMC were treated with IFN- (300 U/ml) or transfected with PKR-specific siRNA or RNase L-specific siRNA. At
7 h posttreatment or 72 h posttransfection, the cells were harvested and subjected to Western blot analysis, using anti-PKR antibody (BD), anti-RNase
L antibody (Abcam), or anti-	-actin antibody. (C) HIV-1NL4-3 viruses were allowed to infect resting or PHA-activated CD4 T cells (3 10
6) (multiplicity
of infection, 0.1). Simultaneously, the infected cells were treated with or without IFN- (300 U/ml) for various periods. For the infected activated CD4
T cells, the culture was maintained in RPMI 1640-conditioned medium containing IL-2 (25 U/ml). The HIV-1 p24 antigen in the supernatant was
harvested every 3 days and detected by ELISA. For the infected resting CD4 T cells, however, PHA (5 g/ml) was added into the cultures at 72 h
postinfection. After 48 h, PHA was removed and the activated cells were cultured in RPMI 1640-conditioned medium containing IL-2 (25 U/ml). The
HIV-1 p24 antigen in the supernatant was harvested every 3 days and detected by ELISA. (D) The resting CD4 T cells (3  106) were transfected with
or without APOBEC3G-specific siRNA or luciferase-specific siRNA. After 72 h, the transfected or untransfected resting CD4 T cells were infected with
HIV-1NL4-3 viruses (multiplicity of infection, 0.1) for 4 h. Simultaneously, the infected cells were treated with or without IFN- (300 U/ml) for 96 h. After
IFN- was washed off, PHA (5 g/ml) was added to stimulate the cells for 48 h. After PHA was removed, the activated cells were cultured in RPMI
1640-conditioned medium containing IL-2 (25 U/ml). The HIV-1 p24 antigen in the supernatant was harvested every 3 days and detected by ELISA.
These data represent at least three independent experiments.
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restriction mediated by APOBEC3G at its normal concentra-
tion. These differences are of great in vivo relevance. HIV-1
could infect resting CD4 T cells and then be restricted by basic
APOBEC3G in vivo. However, the infected resting CD4 T
cells could be activated by antigen or cytokine stimulation at
any moment. Upon activation, APOBEC3G will be associated
with a high molecular mass rather than an LMM, and its
inhibitory effect upon HIV-1 could be decreased. Therefore,
the viruses blocked at the preintegration stage will continue
their life cycle. However, if the IFN-/APOBEC3G pathway is
activated in resting CD4 T cells, the viruses blocked at the
preintegration period will be inactivated and no live viruses will
FIG. 8—Continued.
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be produced upon activation. In summary, our work has dem-
onstrated that interferon, a well-known antiviral innate immu-
nity system, can potently regulate the expression and distribu-
tion of APOBEC3G in CD4 T cells. Similar results have been
reported for macrophages and hepatocytes (21, 30). Therefore,
the connection between two important antiviral innate immu-
nity systems, the interferon system and APOBEC3G and its
family members, has been identified.
We have simultaneously examined the pattern of the
APOBEC3G-associated complex in the activated cells treated
with IFN-, along with several other treatments. As shown in
Fig. 5, the majority of APOBEC3G is associated with an LMM
in the activated CD4 T cells treated with IFN-. It should
be emphasized, however, that the total concentration of
APOBEC3G in the activated CD4 T cells is significantly de-
creased by IFN- (Fig. 1). Therefore, the antiviral effect of
LMM-associated APOBEC3G could be quite limited in the
activated CD4 T cells. Conversely, as APOBEC3G has already
been associated with an LMM in activated CD4 T cells treated
with IFN-, the poor replication of HIV-1 in the activated
phase of CD4 T cells which are initially treated with IFN- at
their resting phase could not be due to the possible “locked”
LMM-associated APOBEC3G which occurs during the resting
stage of cells. Instead, it is more likely due to the fact that the
viral infectivity is significantly inactivated in the resting stage by
the treatment of IFN-. The single-round infection experi-
ments with a reporter gene and intracellular reverse transcrip-
tion have further supported this hypothesis (Fig. 7B and 8A).
Furthermore, the inhibitory effect of IFN- delivered tran-
siently or continuously to the activated CD4 T cells upon
HIV-1 replication is much less than the inhibitory effect of
IFN- delivered transiently to the initially quiescent CD4 T
cells upon HIV-1 replication (Fig. 8C), which also supports this
hypothesis.
Previous studies have already demonstrated that IFN- has
anti-HIV-1 activity for which several mechanisms have been
proposed. It can inhibit the process of reverse transcription at
an early stage, restrict the generation of viral particles but not
viral proteins in chronically infected cells, down-regulate viral
protein synthesis, or suppress the HIV-1 LTR promoter (6, 23,
26, 32). It is noteworthy that the addition of IFN- into cell
cultures of resting primary T lymphocytes before mitogen stim-
ulation could have a much stronger inhibitory effect on reverse
transcription (26), which is consistent with our observations
(Fig. 8A and D). Moreover, IFN- has been used in clinical
trials to treat HIV-1-infected individuals. However, findings
from early clinical trials in the pre-highly active antiretroviral
therapy (HAART) era have shown that IFN- plus reverse
transcriptase inhibitor(s) is effective but unable to completely
control HIV-1 replication (1). It should be emphasized, how-
ever, that HIV-1 extensively replicates in the replicating CD4
T cells and quickly kills them in the pre-HAART era. As
IFN- does not enhance the concentration of APOBEC3G in
replicating CD4 T cells, APOBEC3G could not play a leading
role for IFN- to restrict HIV-1 replication in replicating CD4
T cells. In this report, we have demonstrated that APOBEC3G
is IFN- inducible and makes important contributions for the
anti-HIV-1 activity of IFN- in resting CD4 T cells. As
APOBEC3G potently inhibits the reverse transcription of
HIV-1 in resting T lymphocytes, IFN-enhanced APOBEC3G
expression could mediate the potent inhibitory effect upon
reverse transcription by IFN-. Importantly, because the inac-
tivation of HIV-1 in resting CD4 T cells by the IFN-/
APOBEC3G pathway is so remarkable, it could lead to a novel
therapeutic strategy for IFN- to treat HIV-1-infected individ-
uals. Intriguingly, a very preliminary study has shown that
IFN- in combination with HAART could be more effective in
decreasing viral RNA in blood plasma and PBMC-associated
viral RNA and DNA than HAART alone (10).
It is notable that the concentrations of IFN- observed in
these experiments are relatively high compared to the concen-
trations in the blood plasma of individuals administrated
IFN- (24). However, these experiments are “proof-of-con-
cept” experiments. In the coming experiments, we are going to
investigate the effect of IFN- at “realistic” concentrations
upon intracellular APOBEC3G and anti-HIV-1 activity. As the
first step of a series of in vivo experiments, it is interesting to
investigate whether IFN- which is administrated with a reg-
ular dose could enhance the expression of APOBEC3G in
resting CD4 T cells.
In the post-HAART era, the replication of HIV-1 in repli-
cating CD4 T cells is significantly prevented. Latent HIV-1
infection is the major obstacle in eradicating residual HIV-1
viruses. It has been demonstrated that resting CD4 T cells are
the major reservoirs for HIV-1 viruses. HIV-1 may maintain
latency in these cells by postintegration latency in the memory
CD4 T cells or by a “cryptic” low-level replication (12, 22, 41).
There have been many attempts to eradicate residual HIV-1. It
is likely that APOBEC3G at its normal concentration in resting
CD4 T cells cannot block this replication. Based on our find-
ings, we propose to prevent residual HIV-1 replication by
strengthening APOBEC3G-mediated intracellular innate im-
munity. If IFN- is regularly administrated, or alternatively,
secreted by interferon-producing cells (28) stimulated with cer-
tain cytokines, up-regulation of APOBEC3G in resting CD4 T
cells could block HIV-1 viruses to complete the “cryptic” low-
level replication or abort the established latency, at least the
preintegration latency. Our finding could start a “new think-
ing” to reevaluate IFN- in HIV/AIDS clinics, especially when
we do not have any other reliable way to control the “cryptic”
replication at present.
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